Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

Pharmacogenomics Journal

Volumn 11, Issue 1, 2011, Pages 61-71

  Glimelius, B ^a,b   Garmo, H ^c,d   Berglund, A ^a   Fredriksson, L A ^a   Berglund, M ^a   Kohnke, H ^a   Bystrom P ^b   Sorbye H ^e   Wadelius, M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

camptothecin analogs and derivatives; fluorouracil; glucuronosyltransferase; methylenetetrahydrofolate reductase (NADPH2); P glycoprotein; thymidylate synthase

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; CIPROFLOXACIN; COLONY STIMULATING FACTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; THYMINE;

ABCB1 GENE; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CHOLINERGIC SYMPTOM; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; TYMS GENE; UGT1A1 GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENOTYPE; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEUTROPENIA; P-GLYCOPROTEIN; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 79151469394     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.10     Document Type: Article

References (52)

1. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol 2002; 20: 7-8.
2. Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005; 28: 417-433.
3. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S et al. Phenotypegenotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65: 576-582.
4. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 1049-1051.
5. Innocenti F, Ratain MJ. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther 2004; 75: 495-500.
6. Kim TW, Innocenti F. Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 2007; 29: 265-270.
7. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008; 34: 656-669.
8. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-581.
9. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
10. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515.
11. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004; 44: 854-860.
12. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-2465.
13. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
14. Deeken JF, Slack R, Marshall JL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer 2008; 113: 1502-1510.
15. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
16. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8: 278-288.
17. Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112: 1932-1940.
18. Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99: 275-282.
19. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061-3068.
20. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-5159.
21. Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13: 3269-3275.
22. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290-1295.
23. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678-682.
24. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106: 1007-1016.
25. Fakih MG, Ross ME, Starostik P. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Clin Colorectal Cancer 2007; 6: 583-587.
26. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11: 1226-1236.
27. Romero RZ, Morales R, Garcia F, Huarriz M, Bandres E, De la Haba J et al. Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep 2006; 16: 497-503.
28. Ando M, Hasegawa Y, Ando Y. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs 2005; 23: 539-545.
29. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-2244.
30. Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T et al. Close association of UGT1A9 IVS1+399C4T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos 2009; 37: 272-276.
31. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604-2614.
32. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246-3253.
33. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003; 13: 741-757.
34. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-147.
35. Robien K, Boynton A, Ulrich CM. Pharmacogenetics of folaterelated drug targets in cancer treatment. Pharmacogenomics 2005; 6: 673-689.
36. Iyer L, Ratain MJ. 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 1999; 17: 494-506.
37. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 50-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-197.
38. Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 2008; 9: 1079-1099.
39. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-1369.
40. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868-1873.
41. Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit KM et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (LV5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 909-914.
42. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
43. Cao W, Hashibe M, Rao JY, Morgenstern H, Zhang ZF. Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 2003; 27: 397-404.
44. Saito K, Miyake S, Moriya H, Yamazaki M, Itoh F, Imai K et al. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin Biochem 2003; 36: 511-518.
45. Robien K, Ulrich CM, Bigler J, Yasui Y, Gooley T, Bruemmer B et al. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res 2004; 10: 7592-7598.
46. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.
47. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
48. Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 2005; 92: 1055-1062.
49. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58: 353-356.
50. Mercke Odeberg J, Andrade J, Holmberg K, Hoglund P, Malmqvist U, Odeberg J. UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol 2006; 62: 829-837.
51. Sorbye H, Kohne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007; 18: 1666-1672.
52. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.